Browsing Tag
Indivior PLC
1 post
Indivior (Nasdaq: INDV) study supports 300 mg SUBLOCADE dose for fentanyl-heavy opioid use cases
Indivior’s new trial results highlight how higher-dose SUBLOCADE may better support fentanyl users in OUD treatment. See what this means for the industry.